Profile of farletuzumab and its potential in the treatment of solid tumors, PMID: 27022278
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity, PMID: 30262588
Farletuzumab in lung cancer, PMID: 23357463
Farletuzumab in epithelial ovarian carcinoma, PMID: 20092424
Exploiting the folate receptor α in oncology, PMID: 32152484
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys, PMID: 29928988
Evaluation of therapeutic efficacy of 211 At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer, PMID: 32987283
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer, PMID: 23474348
Role of farletuzumab in epithelial ovarian carcinoma, PMID: 22591419
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro, PMID: 22644798
Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy, PMID: 25363562
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125, PMID: 29041009
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study, PMID: 20855460
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer, PMID: 26644263
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer, PMID: 22955257
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse, PMID: 27001568
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging, PMID: 28826214
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer, PMID: 28450240
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors, PMID: 25380636
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity, PMID: 24025360
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors, PMID: 33926914
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives, PMID: 25765457
Clinical translation of folate receptor-targeted therapeutics, PMID: 22663189
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer, PMID: 23863359
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors, PMID: 26136852
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications, PMID: 25564455
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement, PMID: 28881712
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments, PMID: 26063635
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review, PMID: 25031539
Major clinical research advances in gynecologic cancer in 2013, PMID: 25045437
CA125 effects on humoral immunosuppression, PMID: 29016358
Antibodies to watch in 2013: Mid-year update, PMID: 23727858
Monoclonal antibodies in gynecological cancer: a critical point of view, PMID: 22235224
Which are the antibodies to watch in 2013?, PMID: 23254906
Molecular/genetic therapies in ovarian cancer: future opportunities and challenges, PMID: 22343235
Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging, PMID: 24732155
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer, PMID: 24109193
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer, PMID: 27797594
Clinical trials and future potential of targeted therapy for ovarian cancer, PMID: 22926640
Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer, PMID: 34185411
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast, PMID: 30268765
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding, PMID: 30144039
Gateways to clinical trials, PMID: 18985183
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models, PMID: 33756060
Antibody-based therapeutics to watch in 2011, PMID: 21051951
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer, PMID: 25416196
Folate receptor-α (FOLR1) expression and function in triple negative tumors, PMID: 25816016
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland, PMID: 21441785
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003, PMID: 18355690
MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer, PMID: 18058577
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models., PMID:40074693
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors., PMID:39853764
Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis., PMID:39677200
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448
Integrating antibody drug conjugates in the management of gynecologic cancers., PMID:36878560
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer., PMID:36758420
Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer., PMID:34185411
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors., PMID:33926914
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models., PMID:33756060
Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer., PMID:32987283
Exploiting the folate receptor α in oncology., PMID:32152484
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast., PMID:30268765
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity., PMID:30262588
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding., PMID:30144039
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys., PMID:29928988
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125., PMID:29041009
CA125 effects on humoral immunosuppression., PMID:29016358
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement., PMID:28881712
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging., PMID:28826214
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer., PMID:28450240
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer., PMID:27797594
Profile of farletuzumab and its potential in the treatment of solid tumors., PMID:27022278
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse., PMID:27001568
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer., PMID:26644263
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors., PMID:26136852
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments., PMID:26063635
Folate receptor-α (FOLR1) expression and function in triple negative tumors., PMID:25816016
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives., PMID:25765457
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications., PMID:25564455
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer., PMID:25416196
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors., PMID:25380636
Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy., PMID:25363562
Major clinical research advances in gynecologic cancer in 2013., PMID:25045437
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review., PMID:25031539
Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging., PMID:24732155
International Association for the Study of Lung Cancer - 15th World Conference on Lung Cancer (October 27-31, 2013 - Sydney, Australia)., PMID:24524099
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer., PMID:24109193
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity., PMID:24025360
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer., PMID:23863359
Antibodies to watch in 2013: Mid-year update., PMID:23727858
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer., PMID:23474348
Farletuzumab in lung cancer., PMID:23357463
Which are the antibodies to watch in 2013?, PMID:23254906
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer., PMID:22955257
Clinical trials and future potential of targeted therapy for ovarian cancer., PMID:22926640
Clinical translation of folate receptor-targeted therapeutics., PMID:22663189
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro., PMID:22644798
Role of farletuzumab in epithelial ovarian carcinoma., PMID:22591419
Molecular/genetic therapies in ovarian cancer: future opportunities and challenges., PMID:22343235
Monoclonal antibodies in gynecological cancer: a critical point of view., PMID:22235224
For research use only. Not for human or drug use.
